ALEXIS GURECKI: Open Payments
NPI 1831329598 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,910 in 72 payments from 18 companies in 2025. Trend: 2023 $1,324 · 2024 $1,039 · 2025 $1,910
Food & beverage: $1,820Education: $90
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $308 |
| Regeneron Healthcare Solutions, Inc. | 8 | $239 |
| Ipsen Biopharmaceuticals, Inc | 4 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $186 |
| ABBVIE INC. | 9 | $182 |
| QOL Medical, LLC | 6 | $150 |
| Ardelyx, Inc. | 5 | $124 |
| Optinose US, Inc. | 4 | $83 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $76 |
| Genentech USA, Inc. | 3 | $71 |
Products named: TREMFYA, DUPIXENT, IQIRVO, ENTYVIO, Sucraid, IBSRELA, Xhance, XIFAXAN.
Industry payments across VA — which companies pay providers there.
